Skip to main content

Progress in ALS science and therapeutic development

Latest news

Read our latest announcements on AP-101
March 19, 2026
Additional Phase 2 Data of AL-S Pharma’s Lead Program AP-101 Further Demonstrate Clinically Meaningful Disease Modification and Prolonged Survival in ALS
Read more
January 07, 2026
AL-S Pharma to present at the upcoming J. P. Morgan 2026 Annual Healthcare Conference on Thursday, January 15
Read more
December 05, 2025
AL-S Pharma Reports Positive Results from Phase 2 Study of AP-101 for the Treatment of ALS, Supporting Plans for a Confirmatory Phase 3 Study
Read more
September 25, 2025
AL-S Pharma Appoints Internationally Recognized Neurologist and Clinical Trial Expert Prof. Dr. Angela Genge as Chief Medical Officer
Read more
September 04, 2025
AL-S Pharma Announces Positive Topline Results From Phase 2 Study of AP-101 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Read more

    Upcoming events

    We regularly participate in scientific conferences, partnering forums, and industry meetings. Stay up to date on where you can meet us.
    July 12-15, 2026
    21st Alzheimer’s Association International Conference
    Learn more
    June 22-25, 2026
    BIO International Convention
    Learn more